Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL274964 | 0.91 | KDM4E (0.70) | MAPTALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL6864771 | 0.89 | MAPT (0.52) | MAPTALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL13338845 | 0.88 | KDM4E (0.55) | MAPTALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL13338844 | 0.88 | KDM4E (0.55) | MAPTALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL14021074 | 0.88 | KDM4E (0.51) | MAPTALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL13338859 | 0.85 | KDM4E (0.51) | MAPTALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL34468489 | 0.84 | GAA (0.53) | MAPTALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL13338865 | 0.84 | KDM4E (0.57) | MAPTALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL6864932 | 0.84 | ALDH1A1 (0.54) | MAPTALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL13338870 | 0.83 | KDM4E (0.56) | MAPTALDH1A1KDM4ENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117795020-A | Active energy ray-curable ink, ink set, and image recording method | 富士胶片株式会社 | 2024-03-29 | — | — | CN | disclosed |
| EP-2192163-B1 | Ink composition and inkjet recording method | FUJIFILM CORP (JP) | 2017-04-19 | — | — | EP | disclosed |
| US-8557889-B2 | Ink composition and inkjet recording method | FUJIFILM CORPORATION (JP) | 2013-10-15 | — | — | US | disclosed |
| US-8557889-B2 | Ink composition and inkjet recording method | FUJIFILM CORPORATION (JP) | 2013-10-15 | — | — | US | disclosed |
| US-20100129565-A1 | INK COMPOSITION AND INKJET RECORDING METHOD | FUJIFILM CORPORATION (JP) | 2010-05-27 | — | — | US | disclosed |
| US-20100129565-A1 | INK COMPOSITION AND INKJET RECORDING METHOD | FUJIFILM CORPORATION (JP) | 2010-05-27 | — | — | US | disclosed |
| US-7511064-B2 | Derivatives of 4-(thio- or selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-HT2B receptor antagonist | BIOFRONTERA BIOSCIENCE GMBH (DE) | 2009-03-31 | — | — | US | disclosed |
| US-7511064-B2 | Derivatives of 4-(thio- or selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-HT2B receptor antagonist | BIOFRONTERA BIOSCIENCE GMBH (DE) | 2009-03-31 | — | — | US | disclosed |
| US-7511064-B2 | Derivatives of 4-(thio- or selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-HT2B receptor antagonist | BIOFRONTERA BIOSCIENCE GMBH (DE) | 2009-03-31 | — | — | US | disclosed |
| US-20060183905-A1 | DERIVATIVES OF 4-(THIO-OR SELENOXANTHENE-9-YLIDENE)-PIPERIDINE OR ACRIDINE AND ITS USE AS A SELECTIVE 5-HT2B RECEPTOR ANTAGONIST | BIOFRONTERA BIOSCIENCE GMBH (DE) | 2006-08-17 | — | — | US | disclosed |
| EP-1438307-A2 | DERIVATIVES OF 4-(THIO- OR SELENOXANTHENE-9-YLIDENE)-PIPERIDINE OR ACRIDINE AND ITS USE AS A SELECTIVE 5-HT2B RECEPTOR ANTAGONIST | Biofrontera Pharmaceuticals GmbH (DE) | 2004-07-21 | — | — | EP | disclosed |
| US-20030166672-A1 | Derivatives of 4-(Thio- or Selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-HT2B receptor antagonist | BIOFRONTERA BIOSCIENCE GMBH (DE) | 2003-09-04 | — | — | US | disclosed |
| EP-1321169-A1 | Combination of a serotonin receptor antagonist with a histidine decarboxylase inhibitor as a medicament | Biofrontera Pharmaceuticals AG (DE) | 2003-06-25 | — | — | EP | disclosed |
| EP-1306376-A1 | Derivatives of 4-(thio- or selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-HT2B receptor antagonist | Biofrontera Pharmaceuticals AG (DE) | 2003-05-02 | — | — | EP | disclosed |
| WO-2003035646-A2 | DERIVATIVES OF 4-(THIO- OR SELENOXANTHENE-9-YLIDENE)-PIPERIDINE OR ACRIDINE AND ITS USE AS A SELECTIVE 5-HT2B RECEPTOR ANTAGONIST | BIOFRONTERA PHARMACEUTICALS GMBH (DE) | 2003-05-01 | — | — | WO | disclosed |
| US-20030022920-A1 | 1-Methyl-4- (3-ethoxy-9H-thioxanthene-9-ylidene) -piperidine and its use as 5-HT2B/H1 receptor antagonist | BIOFRONTERA PHARMACEUTICALS AG (DE) | 2003-01-30 | — | — | US | disclosed |
| EP-1270568-A1 | 1-methyl-4-(3-ethoxy-9h-thioxanthene-ylidene)-piperidine and its use as 5-HT2B and/or H1 antagonist | Biofrontera Pharmaceuticals AG (DE) | 2003-01-02 | — | — | EP | disclosed |
| WO-2002102797-A1 | 1-METHYL-4-(3-ETHOXY-9H-THIOXANTHENE-9-YLIDENE)-PIPERIDINE AND ITS USE AS 5-HT2B AND/OR H1 ANTAGONIST | BIOFRONTERA AG (DE) | 2002-12-27 | — | — | WO | disclosed |
| US-6054501-A | CURABILITY; GLOSSINESS; CAN BE BLENDED WITH INKS, PAINTS | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2000-04-25 | — | — | US | disclosed |
| EP-0844255-A1 | PHOTOPOLYMERIZATION INITIATOR AND ACTINIC RADIATION-CURABLE COMPOSITION COMPRISING THE SAME | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1998-05-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166672-A1 | Derivatives of 4-(Thio- or Selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-HT2B receptor antagonist | HTR2B, HTR1B, HTR3B | MAPT 3324/4885ALDH1A1 547/4885KDM4E 3400/4885 |
| US-20060183905-A1 | DERIVATIVES OF 4-(THIO-OR SELENOXANTHENE-9-YLIDENE)-PIPERIDINE OR ACRIDINE AND ITS USE AS A SELECTIVE 5-HT2B RECEPTOR ANTAGONIST | HTR2B, HTR1B, HTR3B | MAPT 3324/4885ALDH1A1 547/4885KDM4E 3400/4885 |
| US-20030022920-A1 | 1-Methyl-4- (3-ethoxy-9H-thioxanthene-9-ylidene) -piperidine and its use as 5-HT2B/H1 receptor antagonist | HTR2B, HTR1B, HTR1A | MAPT 2999/4885ALDH1A1 518/4885KDM4E 477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.